David Nierengarten
Stock Analyst at Wedbush
(3.48)
# 850
Out of 4,884 analysts
206
Total ratings
41.01%
Success rate
6.53%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Reiterates: Neutral | $0.4 | $1.91 | -79.06% | 8 | Jun 26, 2025 | |
| ARGX argenx SE | Reiterates: Outperform | $715 | $543.48 | +31.56% | 21 | Jun 24, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.68 | +198.91% | 4 | Jun 23, 2025 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $16.07 | +36.90% | 2 | Jun 12, 2025 | |
| NUVB Nuvation Bio | Maintains: Outperform | $5 | $2.09 | +139.23% | 9 | Jun 11, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Neutral | $128 → $129 | $128.35 | +0.51% | 5 | Jun 2, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $10 → $12 | $10.18 | +17.88% | 3 | May 28, 2025 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $10 | $10.74 | -6.89% | 9 | May 19, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $29 → $27 | $17.71 | +52.46% | 8 | Apr 16, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Reiterates: Outperform | $34 | $27.88 | +21.95% | 3 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $8.84 | +273.30% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $0.76 | +162.05% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.12 | +346.43% | 15 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $9.03 | +243.30% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $23.75 | +68.42% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $47.46 | +89.63% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $35.99 | +30.59% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $80.48 | +42.89% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $4.30 | +434.88% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $10.80 | +85.19% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $12.60 | +217.46% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $15.76 | +185.53% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.51 | +562.25% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $1.61 | +1,018.01% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $54.75 | +4.11% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.34 | +1,357.73% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.33 | +50.38% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $7.58 | +31.93% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $8.42 | +327.55% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.11 | +285.85% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $20.01 | +184.86% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $7 | $0.29 | +2,317.96% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.85 | +12,887.01% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $4.39 | +1,266.74% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $8.80 | +115.91% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $39.91 | +87.92% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.07 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.20 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.44 | - | 3 | Nov 20, 2017 |
Vor Biopharma
Jun 26, 2025
Reiterates: Neutral
Price Target: $0.4
Current: $1.91
Upside: -79.06%
argenx SE
Jun 24, 2025
Reiterates: Outperform
Price Target: $715
Current: $543.48
Upside: +31.56%
Perspective Therapeutics
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.68
Upside: +198.91%
Telix Pharmaceuticals
Jun 12, 2025
Reiterates: Outperform
Price Target: $22
Current: $16.07
Upside: +36.90%
Nuvation Bio
Jun 11, 2025
Maintains: Outperform
Price Target: $5
Current: $2.09
Upside: +139.23%
Blueprint Medicines
Jun 2, 2025
Downgrades: Neutral
Price Target: $128 → $129
Current: $128.35
Upside: +0.51%
iTeos Therapeutics
May 28, 2025
Downgrades: Neutral
Price Target: $10 → $12
Current: $10.18
Upside: +17.88%
Intellia Therapeutics
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $10.74
Upside: -6.89%
NovoCure
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $17.71
Upside: +52.46%
Kiniksa Pharmaceuticals International,
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $27.88
Upside: +21.95%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $8.84
Upside: +273.30%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.76
Upside: +162.05%
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.12
Upside: +346.43%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $9.03
Upside: +243.30%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $23.75
Upside: +68.42%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $47.46
Upside: +89.63%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $35.99
Upside: +30.59%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $80.48
Upside: +42.89%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $4.30
Upside: +434.88%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $10.80
Upside: +85.19%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $12.60
Upside: +217.46%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $15.76
Upside: +185.53%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.51
Upside: +562.25%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $1.61
Upside: +1,018.01%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $54.75
Upside: +4.11%
Aug 8, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.34
Upside: +1,357.73%
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.33
Upside: +50.38%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $7.58
Upside: +31.93%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $8.42
Upside: +327.55%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.11
Upside: +285.85%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $20.01
Upside: +184.86%
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $0.29
Upside: +2,317.96%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.85
Upside: +12,887.01%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $4.39
Upside: +1,266.74%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $8.80
Upside: +115.91%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $39.91
Upside: +87.92%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.07
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.20
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $6.44
Upside: -